BACKGROUND: The purpose of the present study was to determine cobalt and chromium ion levels in the blood and urine of patients in whom a modern-generation metal-on-metal hip resurfacing device had been implanted. METHODS: A total of ninety-seven patients with a Conserve Plus metal-on-metal hip resurfacing implant were followed prospectively for two years. Cobalt and chromium levels in erythrocytes, serum, and urine were measured preoperatively as well as three, six, twelve, and twenty-four months postoperatively. RESULTS: The median serum cobalt and chromium ion levels were 1.04 μg/L (range, 0.31 to 7.42 μg/L) and 2.00 μg/L (range, 0.28 to 10.49 μg/L), respectively, at one year after surgery and 1.08 μg/L (range, 0.44 to 7.13 μg/L) and 1.64 μg/L (range, 0.47 to 10.95 μg/L), respectively, at two years after surgery. The corresponding mean levels (and standard deviations) of serum cobalt and chromium were 1.68 ± 1.66 μg/L and 2.70 ± 2.22 μg/L, respectively, at one year after surgery and 1.79 ± 1.66 μg/L and 2.70 ± 2.37 μg/L, respectively, at two years after surgery. CONCLUSIONS: These levels compare favorably with other published ion results for metal-on-metal hip resurfacing and replacement implants. No pseudotumors or other adverse soft-tissue reactions were encountered in our study population. Further research is needed to determine the clinical importance of increased cobalt and chromium ion levels in serum and urine following metal-on-metal hip resurfacing.
BACKGROUND: The purpose of the present study was to determine cobalt and chromium ion levels in the blood and urine of patients in whom a modern-generation metal-on-metal hip resurfacing device had been implanted. METHODS: A total of ninety-seven patients with a Conserve Plus metal-on-metal hip resurfacing implant were followed prospectively for two years. Cobalt and chromium levels in erythrocytes, serum, and urine were measured preoperatively as well as three, six, twelve, and twenty-four months postoperatively. RESULTS: The median serum cobalt and chromium ion levels were 1.04 μg/L (range, 0.31 to 7.42 μg/L) and 2.00 μg/L (range, 0.28 to 10.49 μg/L), respectively, at one year after surgery and 1.08 μg/L (range, 0.44 to 7.13 μg/L) and 1.64 μg/L (range, 0.47 to 10.95 μg/L), respectively, at two years after surgery. The corresponding mean levels (and standard deviations) of serum cobalt and chromium were 1.68 ± 1.66 μg/L and 2.70 ± 2.22 μg/L, respectively, at one year after surgery and 1.79 ± 1.66 μg/L and 2.70 ± 2.37 μg/L, respectively, at two years after surgery. CONCLUSIONS: These levels compare favorably with other published ion results for metal-on-metal hip resurfacing and replacement implants. No pseudotumors or other adverse soft-tissue reactions were encountered in our study population. Further research is needed to determine the clinical importance of increased cobalt and chromium ion levels in serum and urine following metal-on-metal hip resurfacing.
Authors: Matteo Cadossi; Silvio Terrando; Andrea Sambri; Giuseppe Tedesco; Antonio Mazzotti; Barbara Bordini; Dalila De Pasquale; Cesare Faldini Journal: Musculoskelet Surg Date: 2017-04-27
Authors: Sulaiman A Almousa; Nelson V Greidanus; Bassam A Masri; Clive P Duncan; Donald S Garbuz Journal: Clin Orthop Relat Res Date: 2013-12 Impact factor: 4.176
Authors: Deborah A Marshall; Karen Pykerman; Jason Werle; Diane Lorenzetti; Tracy Wasylak; Tom Noseworthy; Donald A Dick; Greg O'Connor; Aish Sundaram; Sanne Heintzbergen; Cy Frank Journal: Clin Orthop Relat Res Date: 2014-04-04 Impact factor: 4.176
Authors: James P Yoon; Michel J Le Duff; Alicia J Johnson; Karren M Takamura; Edward Ebramzadeh; Harlan C Amstutz Journal: Clin Orthop Relat Res Date: 2012-11-27 Impact factor: 4.176
Authors: Christopher Jantzen; Henrik L Jørgensen; Benn R Duus; Sune L Sporring; Jes B Lauritzen Journal: Acta Orthop Date: 2013-04-18 Impact factor: 3.717